CJC-1295 with DAC
CJC-1295 with DAC is investigated as a long-acting analog of growth hormone-releasing hormone (GHRH). Scientific studies primarily examine its extended half-life and its continuous stimulation of the GH/IGF-1 axis.
Limited HumanEndocrine Research
Formula
C₁₆₅H₂₆₉N₄₇O₄₆
MW
3647.2 g/mol
Half-life
≈6–8 days (reported in literature, albumin-binding DAC moiety)
Studies
2
Research Material · Uptide.eu
View Research Material →Access product specifications, COA documentation and research material on Uptide.
Research overview
CJC-1295 with DAC is actively investigated as a long-acting analog of growth hormone-releasing hormone (GHRH). The Drug Affinity Complex (DAC) technology was specifically developed to promote molecular binding to endogenous blood albumin, thereby significantly extending the peptide's biological half-life. Scientific studies primarily examine its ability to alter pulsatile growth hormone secretion and persistently elevate insulin-like growth factor 1 (IGF-1) levels over several days following a single experimental administration. The primary research question involves the complex endocrine regulation of the GH/IGF-1 axis rather than assessing direct physiological performance or recovery parameters in human subjects.
Synonyms
DAC:GRF, CJC-1295 DAC
Classification
Long-acting GHRH analog
Molecular weight
3647.2 g/mol
Molecular formula
C₁₆₅H₂₆₉N₄₇O₄₆
CAS Number
863288-34-0
Half-life
≈6–8 days (reported in literature, albumin-binding DAC moiety)
Evidence level
Limited Human
Research areas
Endocrine Research
Pathways
GH/IGF-1 axis, GHRH receptor signalling
Related compounds
Frequently co-cited in the literature
Research disclaimer
All information is provided for educational and scientific research purposes only. No content constitutes medical advice, treatment recommendations, administration guidance or dosing recommendations. Products referenced are intended for laboratory and analytical research.